Decreased placental glypican expression is associated with human fetal growth restriction.


Journal

Placenta
ISSN: 1532-3102
Titre abrégé: Placenta
Pays: Netherlands
ID NLM: 8006349

Informations de publication

Date de publication:
15 01 2019
Historique:
received: 21 12 2016
revised: 05 12 2018
accepted: 17 12 2018
entrez: 27 2 2019
pubmed: 26 2 2019
medline: 13 3 2020
Statut: ppublish

Résumé

Placental mediated fetal growth restriction (FGR) is a leading cause of perinatal morbidity and mortality. Heparan sulphate proteoglycans (HSPG) are highly expressed in placentae and regulate haemostasis. We hypothesise that altered expression of HSPGs, glypicans (GPC) may contribute to the development of FGR and small-for-gestational-age (SGA). GPC expression was determined in first-trimester chorionic villous samples collected from women with later SGA pregnancies and in placentae from third-trimester FGR and gestation-matched uncomplicated pregnancies. The expression of both GPC1 and GPC3 were significantly reduced in first-trimester SGA as well as in the third-trimester FGR placentae compared to controls. This is the first study to report a relationship between altered placental GPC expression and subsequent development of SGA/FGR.

Identifiants

pubmed: 30803713
pii: S0143-4004(18)31204-9
doi: 10.1016/j.placenta.2018.12.007
pii:
doi:

Substances chimiques

Glypicans 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6-9

Informations de copyright

Copyright © 2018. Published by Elsevier Ltd.

Auteurs

T Gunatillake (T)

Department of Obstetrics and Gynaecology, The University of Melbourne, Sunshine Hospital, St Albans, 3021, Australia. Electronic address: gunatillake.t@unimelb.edu.au.

A Chui (A)

Department of Obstetrics and Gynaecology, The University of Melbourne, Sunshine Hospital, St Albans, 3021, Australia.

E Fitzpatrick (E)

Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, 3052, Australia.

V Ignjatovic (V)

Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, 3052, Australia; Department of Clinical Haematology, Royal Children's Hospital, Parkville, 3052, Australia.

P Monagle (P)

Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, 3052, Australia; Department of Paediatrics, The University of Melbourne, Royal Children's Hospital, Parkville, 3052, Australia; Department of Clinical Haematology, Royal Children's Hospital, Parkville, 3052, Australia.

J Whitelock (J)

Graduate School of Biomedical Engineering, University of New South Wales, Kensington, Australia.

D Zanten (D)

Department of Obstetrics and Gynaecology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

J Eijsink (J)

Department of Obstetrics and Gynaecology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

A Borg (A)

Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal Women's Hospital, Parkville, 3052, Australia.

J Stevenson (J)

Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal Women's Hospital, Parkville, 3052, Australia.

S P Brennecke (SP)

Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal Women's Hospital, Parkville, 3052, Australia.

J J H M Erwich (JJHM)

Department of Obstetrics and Gynaecology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

J M Said (JM)

Department of Obstetrics and Gynaecology, The University of Melbourne, Sunshine Hospital, St Albans, 3021, Australia; Maternal Fetal Medicine, Sunshine Hospital, Western Health, St Albans, 3021, Australia.

P Murthi (P)

Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal Women's Hospital, Parkville, 3052, Australia; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, 3052, Australia; Department of Medicine, School of Clinical Sciences, Monash University, Clayton, 3168, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH